Healthcare Quarterly
Using a Quality Improvement Process to Create Measurable Improvement in Care Delivery for Acute Stroke
Rhonda Whiteman, Linda Gould, Wieslaw Oczkowski, Kathryn LeBlanc and Patti Leonard
The introduction of thrombolytic therapy has revolutionized the management of acute ischemic stroke, and it has now been conclusively established that tissue plasminogen activator (t-PA) given within 4.5 hours of stroke onset both limits irreversible ischemic neuronal damage by establishing reperfusion of the penumbra and improves outcomes for patients who have undergone stroke. Clinical trials have demonstrated that in patients who receive t-PA, there is a reduction in disability and a greater chance of having significant recovery (Wardlaw et al. 2009).
Comments
Be the first to comment on this!
This article is for subscribers only. To view the entire article
Related Articles
Note: Please enter a display name. Your email address will not be publically displayed